Phase 2 N=108 Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial
Inflammation · Fibrosis
Primary: Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 12 Months — 0.14; 0.29 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=53 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Phase 2 N=77 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Adult Acute Lymphoblastic Leukemia · Adult Acute Myeloid Leukemia · Adult Diffuse Large B-Cell Lymphoma
Primary: Number of Patients With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 15; 12 Participants
Phase 2 N=5 Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change From Baseline of Plasma Estradiol Levels — -1.26 pg/ml
Phase 2 N=160 A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
Sarcopenia
Primary: Population I: Short Physical Performance Battery (SPPB) Total Score at Week 49 — 8.8; 10.2; 8.0; 8.0 Scores on a scale — p=0.759
Phase 2 N=55 Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip
Osteoarthritis of the Shoulder · Osteoarthritis of the Hip
Primary: Concentration of Triamcinolone Acetonide (TA) in Blood Plasma — 1061.8; 1104.1; 681.8; 3862.3 pg/mL
Phase 2 N=109 Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth
Obesity · Insulin Resistance · Vitamin D Deficiency
Primary: Change in HOMA-IR — 0; -1.5; -1.7 HOMA-IR score
Phase 2 N=9 Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Homozygous Familial Hypercholesterolemia
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) to Week 4 in the Main Study Period — -49.17 Percent Change
Phase 2 N=11 Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
Fabry Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 9 Participants
Phase 2 N=95 Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 93.3; 100.0; 84.2 percentage of participants
Phase 2 N=68 Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
Prostate Cancer
Primary: Proportion of Participants With Pathologic Stage Less Than or Equal to ypT2N0 — 13; 11 Participants
Phase 2 N=38 Spondylitis Trial of Apremilast for Better Rheumatic Therapy
Ankylosing Spondylitis
Primary: Changes of Apremilast in Patients With AS, Changes in BASDAI Score From Baseline — -0.77; -1.59 units on a scale — p=0.139
Phase 2 N=7 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
Frontotemporal Lobar Degeneration (FTLD) · Frontotemporal Dementia (FTD) · Tauopathies
Primary: SUVR of 18F-AV-1451 — 1.07; 1.26; 1.03; 1.34 standardized uptake value ratio (SUVR)
Phase 2 N=8 Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator
Hematologic Neoplasms
Primary: Overview of Adverse Events (Safety Set) — 6; 2; 2; 3 participants
Phase 2 N=24 Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: Change From Baseline in 24-hour Weighted Mean Serum Cortisol — -7.7; -42.7; -62.2; -59.0 weighted mean serum cortisol (nmol/L)